Vimta Labs is engaged in the business of testing food and drugs. It also does contract research for clinical research and pre-clinical studies. Company was expected to give good quarter and has delivered.
VIMTA LABS: Q2 CONS NET PROFIT 97M RUPEES VS 75M (YOY); 81M (QOQ) || Q2 REVENUE 754M RUPEES VS 593M (YOY); 613M (QOQ) DII have bought significantly in the last quarter, Some news is coming up TARGET : See CHART